Niagen Bioscience Inc’s recently made public that its Chief Financial Officer Pamir Ozan acquired Company’s shares for reported $30406.0 on Nov 14 ’25. In the deal valued at $6.81 per share,4,465 shares were bought. As a result of this transaction, Pamir Ozan now holds 7,372 shares worth roughly $50571.920000000006.
Then, Pamir Ozan bought 2,220 shares, generating $15,210 in total proceeds. Upon buying the shares at $6.85, the Chief Financial Officer now owns 2,220 shares.
Before that, Lopez Carlos Luis bought 273 shares. Niagen Bioscience Inc shares valued at $2,146 were divested by the SVP, General Counsel at a price of $7.86 per share. As a result of the transaction, Lopez Carlos Luis now holds 2,251 shares, worth roughly $15441.86.
Canaccord Genuity initiated its Niagen Bioscience Inc [NAGE] rating to a Buy in a research note published on May 27, 2025; the price target was $13. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who decreased its forecast for the stock in mid August from “an Outperform” to “a Perform”. B. Riley Securities also remained covering NAGE and has decreased its forecast on August 11, 2022 with a “Neutral” recommendation from previously “Buy” rating. ROTH Capital started covering the stock on March 08, 2022. It rated NAGE as “a Buy”.
Price Performance Review of NAGE
On Tuesday, Niagen Bioscience Inc [NASDAQ:NAGE] saw its stock fall -1.01% to $6.86. Over the last five days, the stock has lost -4.19%. Niagen Bioscience Inc shares have fallen nearly -4.72% since the year began. Nevertheless, the stocks have risen 29.31% over the past one year. While a 52-week high of $14.69 was reached on 06/30/25, a 52-week low of $5.16 was recorded on 01/07/25.
Levels Of Support And Resistance For NAGE Stock
The 24-hour chart illustrates a support level at 6.70, which if violated will result in even more drops to 6.55. On the upside, there is a resistance level at 7.03. A further resistance level may holdings at 7.21.
How much short interest is there in Niagen Bioscience Inc?
A steep rise in short interest was recorded in Niagen Bioscience Inc stocks on 2025-10-31, growing by 1.33 million shares to a total of 5.08 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 3.75 million shares. There was a rise of 26.1%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 16, 2019 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $6 price target.
